Concomitant RAS , RET/PTC , or BRAF Mutations in Advanced Stage of Papillary Thyroid Carcinoma
Thyroid2014Vol. 24(8), pp. 1256–1266
Citations Over TimeTop 10% of 2014 papers
Minjing Zou, Essa Y. Baitei, Ali S. Alzahrani, Faisal S. BinHumaid, Dania Alkhafaji, Roua A. Al‐Rijjal, Brian F. Meyer, Yufei Shi
Abstract
Our data show that concomitant mutations are a frequent event in advanced PTC and are associated with poor prognosis. The concomitant mutations may represent intratumor heterogeneity and could exert a gene dosage effect to promote disease progression. KRAS(S65N) can constitutively activate the MAPK pathway.
Related Papers
- → Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas(2004)160 cited
- → Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).(2013)43 cited
- → Kras and Hras—what is the difference?(2008)11 cited
- → RAS status in Korean patients with stage III and IV colorectal cancer(2015)7 cited
- → RAS mutations distribution in a 108 patients series of colorectal cancer(2014)